Collaboration aims to leverage Polyrizon's advanced proprietary intranasal delivery platform to support clinical development of Clearmind's drug candidate proprietary MEAI Raanana, Israel, Feb. 06, 20 ...
Collaboration aims to enhance bioavailability and support clinical advancement of Clearmind's lead MEAI candidate for addiction-related and other CNS disorders Vancouver, Canada, Feb. 06, 2026 (GLOBE ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果